INTRODUCTION {#s1}
============

Mast cells (MCs), following c-Kit activation, stimulates angiogenesis in various types of human tumors. Prot-oncogene c-Kit mutation is identified in animal and human tumors including dog mastocytoma, gastrointestinal stromal tumor (GIST) and pancreatic cancer \[[@R1]--[@R4]\].

In 1986 Besmer P et al found the viral *v-kit* sequence and it was demonstrated that this gene was involved in the pathogenesis of the feline sarcoma virus. One year later the cellular corresponding homologue c-Kit gene was also discovered and it was demonstrated that the protein codified by the above gene was a membrane tyrosine kinase receptor \[[@R5]\].

The ligand for c-Kit receptor (c-Kit-R) is the Stem Cell Factor (SCF) and Kit-R is expressed by several cellular kind such as hematopoietic precursor, germ cells, interstitial cells of Cajal, melanocytes, and mainly MCs. With special reference to MCs the activation of c-Kit-R driven the main important cellular function and in particular: survival, proliferation and differentiation \[[@R6]\].

It is now well established that MCs contains a lot of stimulating angiogenic substances, such as Vascular Endothelial Growth Factor (VEGF) \[[@R7]\], Fibroblast Growth Factor-2 (FGF-2) and tryptase. Among them tryptase it is the most represented protein stored in MCs secretory granules and it can be secreted following c-Kit-R activation. In vitro studies indicated that tryptase it own strong angiogenic properties stimulating endothelial cells (ECs) to proliferate in both matrigel and chick embryo chorioallantoic membrane systems. In the last system, the addition of tryptase inhibitors suppressed ECs proliferation and then new blood microvessel formation. At cellular level tryptase binds protease-activated receptor-2 (PAR-2) that is a transmembrane G protein and then the signaling is internalized into the EC leading to their mitosis and finally new vessel formation \[[@R8]--[@R29]\].

With special regard to pacreatic cancer very little literature data have been available on this topic \[[@R30]-[@R32]\].

Here we aim to evaluate by mean of both immunohistochemial and morphometrical assay the density of mast cells positive to c-Kit receptor (c-Kit^+^ MCs), the density of MCs expressing tryptase (MCD-T) and microvessel density (MVD) in a series of 35 pancreatic ductal adenocarcinoma (PDAC) from patients underwent to up-front surgical treatment. In this research area, will be possible to evaluate our preliminary data for novel cancer biomarkers and for novel anti vascular approach in pancreatic tumor treatment.

RESULTS {#s2}
=======

Immunohistochemistry assay utilizing the primary antibodies to c-Kit-R, to tryptase and to CD31 indicated that in more angiogenetic tumor area, so called *hot spots*, MCs are clearly identified close vessels (Figure [1](#F1){ref-type="fig"}).

![Pancreatic cancer tissue sections evaluated by immunohistochemistry\
**(A)** Many red immunostained mast cells positive to c-Kit receptor, arrows indicate single scattered mast cells, note the main membrane cytoplasmic immunostained pattern and the blue nucleus of mast cells is also observed. Big arrow indicates a clusters of pancreatic cancer cells (magnification x400). **(B)** Many red immunostained mast cells positive to tryptase, arrows indicate single scattered mast cells, big arrow indicates a cluster of pancreatic cancer cells (magnification x400). **(C)** Many red immunostained microvessels positive to anti-CD31 antibody, arrows indicate single scattered microvessels, big arrows indicate the red wall of microvessel with a hyaline translucent red blood cells in its lumen (magnification x400).](oncotarget-08-70463-g001){#F1}

The mean value ± standard deviation of c-Kit^+^ MCs, MCD-T and MVD was 13.23 ± 3.92, 12.47 ± 4.32 and 27.34 ± 8.97 respectively. In adjacent non tumoral and non inflamed pancreatic tissue the mean value of c-Kit^+^ MCs, MCD-T and MVD was 5.12 ± 2.10, 4.29 ± 1.20, 11.45 ± 8.59, respectively. These results demontstrated that c-Kit^+^ MCs, MCD-T and MVD are more represented in tumor tissue as compared to normal tissue.

Significantly, in primary tumor tissue, the following association have been obtained between c-Kit^+^ MCs and MVD (r= 0.75, p= 0.04), MCD-T and MVD (r= 0.76, p= 0.03), MCD-T and c-Kit^+^ MCs (r= 0.87 p= 0.01) (Figure [2](#F2){ref-type="fig"}). No correlation concerning c-Kit^+^ MCs, MCD-T and microvessel density and the classical clinico-pathological hallmark has been discovered (data not shown). Cell count per field has been done at magnification 400x (0.19 mm^2^ area). Mean value difference between groups was measured by t test of Student and statistical significance was considered if p was ≤ 0.05.

![Correlation analysis between c-Kit^+^ MCs and MVD (r= 0.75, p= 0.04), MCD-T and MVD (r= 0.76, p= 0.03), between MCD-T and c-Kit^+^ MCs (r= 0.87 p= 0.01)](oncotarget-08-70463-g002){#F2}

DISCUSSION {#s3}
==========

MCs are important in allergic and late-phase reactions, inflammation, and in the regulation of adaptive T-cell--mediated immunity. However, the role of MCs in cancers development is not totally understand, and data about their benefit or detriment to tumorigenesis have been controversial, depending on the local stromal conditions \[[@R33]\].

MCs could stimulate cancer development and progression in several ways. First, tumors can produce substances that attracting MCs in their microenvironment \[[@R33]\]. Second, in tumor microenvironment MCs activation can be triggered by the contact with tumor cells employing the pathway of adenosine/adenosine receptor \[[@R34]\]. Third MCs stimulation can be also triggered by cytokine and growth factor produced by tumor cells such as SCF that binding c-Kit-R lead to MCs activation and degranulation. \[[@R8], [@R35]--[@R36]\]. The final results is the exocytosis of pro-cancer and pro-angiogenetic mediators.

Among them tryptase it is the most represented protein stored in MCs secretory granules. In vitro studies indicated that tryptase it own strong angiogenic properties stimulating ECs to proliferate in both matrigel and chick embryo chorioallantoic membrane systems. In the last system, the addition of tryptase inhibitors suppressed ECs proliferation and then new blood microvessel formation. Tryptase is able to binds PAR-2 on endothelium stimulating the last to proliferate \[[@R8]\].

In other way tryptase indirectly stimulates neovascularization activating matrix metallopreteinases that in turn degrade the extracellular matrix leading to discharge of angiogenic factors in it contained \[[@R37]--[@R40]\].

Recently, pilot research, suggested that MCs are involved in neovascularization of pancreatic cancer and lymph node metastasis. In this manner, MCs presence in primary tumor tissue could influence growth tumor and overall survival of patients \[[@R41]--[@R45]\].

In our study, we have first assessed the status of c-Kit^+^ MCs, MCD-T and MVD in a series of 35 PDACP underwent to surgery. The results of our study need to be considered with some degree of caution due to the small sample of selected T~2-3~-N~0-1~-M~0~ analyzed patients. We chose to focus on the above subset of patients in that they were patients candidate to an up-front surgery treatment. Further awaited confirmatory studies could be more informative extending the analysis to patients with any TNM stages to evaluate possible differences through tumor progression.

To overcame possible methodological bias, the evaluation of the above parameters has been performed by mean of an image analysis system at x400 magnifications in a well defined microscopic area of 0,19 mm^2^ as previously published in other tumors type \[[@R46]\]. Next tissue evaluated parameters have been correlated to each other and results demonstrated a strong correlation between MCs, tryptase and microvascular bed.

On the other hand no correlation with the main clinico-pathological features has been found. From a biometrical point of view our results indicated that increased angiogenesis paralleled with both increased count of c-Kit^+^ MCs and MCD-T. It is interesting to underline that achieve data indicated a spatial localization of MCs mainly close vessels. Based on this histological location of MCs tryptase from them released could in loco act inducing microvessel formation and furthermore it could pass into blood flow facilitating tumor metastasis. In this scenario, tryptase could be degranulated from MCs following c-Kit-R activation. Based on these data we suggest that c-Kit^+^ MCs and MCD-T may be a novel surrogate angiogenic markers in pancreatic cancer patients.

From a translational and clinical point of view, it is intriguing to speculate the inhibition of pancreatic cancer angiogenesis at two different novel targets: first blocking MC activation employing available c-Kit-R inhibitors such as masitinib mesilate and second blocking tryptase utilizing gabexate mesilate or nafamostat mesilate \[[@R47]--[@R56]\]. Further studies in more large series of patients are awaited to confirm our preliminary data together with clinical trials aiming to evaluate the novel suggested therapeutic approaches regarding this very intriguingly topic.

MATERIALS AND METHODS {#s4}
=====================

Study population {#s4_1}
----------------

The clinico-pathological features of selected patients are summarized in Table [1](#T1){ref-type="table"}. A total of 35 PDAC patients with stage T~2-3~N~0-1~M~0~ were undergone to potential curative resection. Surgical approaches used were: pancreaticoduodenectomy, distal pancreatectomy and total pancreatectomy with lymph node dissection. Patients were staged according to the American Joint Committee on Cancer 7^th^ edition (AJCC-TNM) classification and the World Health Organization classification (2000 version) was used for pathologic grading. All patients had not distant metastases on computed tomography. Full ethical approval and signed consent from individual patients was obtained. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the "Mater Domini" Hospital, "Magna Graecia" University, Catanzaro (N° 242; 22 December 2016).

###### Clinico-pathological features of patients (*n*=35)

  ----------------------------- ---------------
  ***Age***                     
  **► \<65**                    **25 (71%)**
  **► \>65**                    **10 (29%)**
  ***Gender***                  
  **►Male**                     **14 (40%)**
  **►Female**                   **21 (60%)**
  ***Tumour site***             
  **►Head**                     **15 (43%)**
  **►Body-Tail**                **20 (57%)**
  ***TNM by AJCC stage***       
  **►T~2~N~0-1~M~0~**           **16 (46%)**
  **►T~3~N~0-1~M~0~**           **19 (54%)**
  ***Histologic type***         
  **►Ductal adenocarcinomas**   **35 (100%)**
  ***Histologic grade***        
  **►G1-G2**                    **27 (77%)**
  **►G3**                       **8 (23%)**
  ----------------------------- ---------------

Immunohistochemistry {#s4_2}
--------------------

For the evaluation of c-Kit^+^ MCs, MCD-T and MVD a three-layer biotin-avidin-peroxidase system was utilized \[[@R57]\]. Briefly, 4 μm thick serial sections of formalin-fixed and paraffin-embedded surgical removed tumor samples were deparaffinised. Then, for antigen retrieval, sections were microwaved at 500W for 10 min, after which endogenous peroxidase activity was blocked with 3% hydrogen peroxide solution. Next, adjacent slides were incubated with the monoclonal antibodies anti-CD31 (QB-END 10; Bio-Optica Milan, Milan, Italy) for the identification of endothelial cells diluted 1:50 for 1 h at room temperature, antibodies anti-c-Kit-R (CD117; Dako) for 30 min and pH 8 for the identification of c-Kit^+^ MCs and antibodies anti-tryptase (clone AA1; Dako, Glostrup, Denmark) for the identification of MCD-T diluted 1:100 for 1 h at room temperature. The bound antibody was visualiszed using biotinylated secondary antibody, avidin-biotin peroxidase complex and fast red. Nuclear counterstaining was performed with Gill\'s haematoxylin no. 2 (Polysciences, Warrington, PA, USA). Primary antibody was omitted in negative controls.

Morphometrical assay {#s4_3}
--------------------

Light microscopy integrated with an image analysis system (AXIO, Scope A1, ZEISS, Gottingen, Germany) was utilized.

Hot spot areas were selected at low magnification. C-Kit^+^ MCs, MCD-T and MVD were counted at x400 magnification (0.19 mm^2^ area, Figure [1A, 1B, 1C](#F1){ref-type="fig"}) \[[@R46]\]. In serial sections, each single c-Kit^+^ MCs and positive to tryptase was counted.

Statistical analysis {#s4_4}
--------------------

Linear correlations between c-Kit^+^ MCs, MCD-T and MVD groups each to other were quantified by means of the Pearson's correlation analysis. Difference between groups was measured by student t test and values were significantly different with p≤ 0.05.

Correlation among c-Kit^+^ MCs, MCD-T and MVD groups and the main clinico-pathological features were analysed by chi-square-test (χ2). All statistical analysis was performed with the SPSS statistical software package (SPSS, Inc., Chicago, IL).
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